Barclays
KZIA

Barclays’s Kazia Therapeutics KZIA Stock Holding History

Barclays’s Portfolio KZIA Stock Details KZIA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$803K Buy
56,999
+33,000
+138% +$402K ﹤0.01% 2929
2026
Q1 		$179K Hold
23,999
– – ﹤0.01% 3756
2025
Q4 		$165K Sell
23,999
-1
-0% -$9 ﹤0.01% 4417
2025
Q3 		$173K Hold
24,000
– – ﹤0.01% 4399
2025
Q2 		$150K Hold
24,000
– – ﹤0.01% 4414
2025
Q1 		$93.9K Hold
24,000
– – ﹤0.01% 4431
2024
Q4 		$212K Buy
+24,000
New +$555K ﹤0.01% 4279

Other funds holding KZIA

BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
FLPIM
F.L. Putnam Investment Management Lynnfield, Massachusetts $8.39B AUM 37.75% 1-Year Est. Return
BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
DIG
Dauntless Investment Group Etna, New Hampshire $127M AUM 42.43% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Barclays's KZIA Position: Q2 2026 in Review

Barclays increased its Kazia Therapeutics (KZIA) stake by 138% in Q2 2026, buying an estimated $402K and bringing the position to 56,999 shares worth $803K. The position accounts for ﹤0.01% of the portfolio, ranked #2929.

Barclays first reported a position in KZIA in Q4 2024 and has held it in 7 quarters since. 35 funds tracked by Wall St. Rank hold KZIA as of Q2 2026.

  • Barclays held 56,999 shares of Kazia Therapeutics worth $803K as of Q2 2026.
  • Barclays bought 33,000 Kazia Therapeutics shares in Q2 2026, an estimated $402K.
  • Kazia Therapeutics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #2929 holding.
  • Barclays first reported a position in Kazia Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 35 funds tracked by Wall St. Rank held Kazia Therapeutics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.